Hengrun Dasheng completed 200 million yuan B-plus round of financing, plus code cell therapy industrialization layout.

Recently, Zhangjiang Science City cell therapy company Shanghai Hengrun Dasheng Biotech Co., Ltd. (hereinafter referred to as "Hangrun Dasheng") announced the completion of 200 million yuan B-plus round of financing, Pudong Science Group, China New Fund, Wanhui Capital, Dongtai Chongye, Xinsilu Investment, Xinyi Capital, Junjunda Capital and Heng Zhen Partnership and other participating investments.
The funds raised will be used to support the further development of clinical trials of three CAR-T batches of Hengrun Dasheng, the commercial development of coded CAR-T products, and to promote the development of pipelines such as CAR-T, TCR-T, CAR-NK and lysovirus for new targets for solid tumors, laying the foundation for subsequent IPOs.
Hengrun Dasheng was founded in 2015, focusing on the research and development and application of tumor immunotherapy technology, as One of China's first batch of enterprises to enter the cell therapy circuit, Hengrun Dasheng has now formed a CAR-T technology-led, targeting solid tumor TCR-T, CAR-NK and somavirus and other research and development projects in parallel to promote the research and development pattern, at the same time has been approved about 80 million yuan of government-funded projects, independently undertake a major national project.
Up to now, Hengrun Dasheng has 18 projects for 12 tumor adaptive CAR-T research and development pipeline, CAR-NK, TCR-T and lysovirus research and development projects are also in progress, the overall pipeline covers the main blood tumors and solid tumor adaptation.
present, Hengrun Dasheng has obtained 3 CAR-T clinical approvals, targeting CD19 and BCMA, respectively, for relapsed/refractic CD19-positive diffuse large B-cell lymphoma and folytic lymphoma The treatment of recurring/recurring/resuscable CD19-positive B-cell acute lymphoblastic leukemia and BCMA-positive relapsed/resuscable multiple myeloma has been carried out simultaneously in the registered clinical of these three batches in the well-known hospitals in China.
At the same time, Hengrun Dasheng and the United States, Israel, the Czech Republic, Hungary and other countries and other relevant departments and medical institutions reached an agreement to carry out extensive cooperation in CAR T drug clinical trial research, of which the Israeli Ministry of Health has approved Hengrun Dasheng CAR-T products into the country's hospitals to carry out CAR-T drug clinical trial research.
At present, Hengrun Dasheng in front-end research and development, CMC research, IND declaration, clinical trial development and other aspects of the formation of a sound technical system, hardware support, the existing research and development of about 5000 square meters and pilot platform, its located in Zhangjiang Jinshan biomedical base of 11,000 square meters of large-scale CAR-T GMP preparation center is about to be completed, for the future large-scale industrialization of cell products to lay a solid foundation.
source: Medical Valley.com!-- content presentation ends -- !-- to determine whether the login ends.